{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T06:58:46Z","timestamp":1722409126755},"reference-count":22,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T00:00:00Z","timestamp":1477267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>This study was designed to investigate which biological agent, infliximab or tocilizumab, would more intensively keep suppressing oxidative stress among well\u2010controlled patients as C\u2010reactive protein (CRP) levels normalized in rheumatoid arthritis (RA). In addition, it was intended to clarify indicative factors of oxidative stress among well\u2010controlled patients with RA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We recruited 61 well\u2010controlled (CRP &lt; 0.3 mg\/dL within normal ranges) patients with RA using biological agents (infliximab <jats:italic>n<\/jats:italic> = 33; tocilizumab <jats:italic>n<\/jats:italic> = 28), active RA patients with CRP &gt; 1.0 mg\/dL (<jats:italic>n<\/jats:italic> = 10) and healthy subjects (<jats:italic>n<\/jats:italic> = 10) and examined the fraction of oxidized albumin (oxidized\u2010albumin [%]) as a marker of oxidative stress in addition to inflammatory measures and disease activity scores such as CRP, erythrocyte sedimentation rate (ESR), matrix metalloproteinase 3 (MMP\u20103), serum amyloid A (SAA), Clinical Disease Activity Index, Simplified Disease Activity Index, visual analog scale (VAS), Disease Activity Index of 28 joints (DAS28)\u2010CRP, DAS28\u2010ESR and renal function (creatinine clearance [CCr]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Oxidized\u2010albumin (%) was significantly elevated among active RA patients (33.83 \u00b1 5.31%) as compared with healthy subjects (23.00 \u00b1 2.56%). Although oxidized\u2010albumin (%) among well\u2010controlled RA patients also increased, there was no difference with oxidized\u2010albumin (%) between infliximab and tocilizumab groups (26.40 \u00b1 5.44% in infliximab; 26.62 \u00b1 4.53% in tocilizumab). In Pearson's correlation, oxidized\u2010albumin (%) had significant correlations with CRP, MMP\u20103, ESR, SAA, age, CCr, VAS, DAS28\u2010CRP and DAS28\u2010ESR. With those variables, multiple stepwise forward regression analysis was conducted and revealed that CCr, DAS28\u2010ESR and CRP are the statistically significant explanatory variables on oxidized\u2010albumin (%) among well\u2010controlled RA patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We demonstrated that there was no difference with infliximab and tocilizumab on oxidative stress and we clarified that CCr, DAS28\u2010ESR and CRP become indicative factors of oxidative stress among well\u2010controlled RA patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.12972","type":"journal-article","created":{"date-parts":[[2016,10,25]],"date-time":"2016-10-25T03:56:43Z","timestamp":1477367803000},"page":"1815-1821","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Infliximab equivalently suppresses oxidative stress compared to tocilizumab among well\u2010controlled patients with rheumatoid arthritis"],"prefix":"10.1111","volume":"21","author":[{"given":"Kazuha","family":"Kizaki","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery and Rheumatology Kyoto Shimogamo Hospital Kyoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiharu","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery and Rheumatology Kyoto Shimogamo Hospital Kyoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Sports Science Meiji University of Integrative Medicine Kyoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Funakoshi","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery and Rheumatology Kyoto Shimogamo Hospital Kyoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,10,24]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000099844.31524.05"},{"key":"e_1_2_9_3_1","first-page":"15","article-title":"Role of reactive oxygen and nitrogen species in etiopathogenesis of rheumatoid arthritis","volume":"18","author":"Bauerova K","year":"2000","journal-title":"Gen Physiol Biophys"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000115557.25127.8D"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.652859"},{"key":"e_1_2_9_6_1","first-page":"73","article-title":"Reduction of oxidative stress marker levels by anti\u2010TNF\u2010alpha antibody, infliximab, in patients with rheumatoid arthritis","volume":"26","author":"Kageyama Y","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-2135-0"},{"key":"e_1_2_9_8_1","first-page":"349","article-title":"Tocilizumab in the treatment of rheumatoid arthritis and beyond","volume":"8","author":"Shetty A","year":"2014","journal-title":"Drug Design Devel Ther"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2013.05.050"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2008.04.057"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2012.4702"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/690953"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400928"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00969.x"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0928-4680(99)00022-X"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker295"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201282"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken386"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000053730.47739.3C"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200051"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204128"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2015.04.011"},{"key":"e_1_2_9_23_1","first-page":"1095","article-title":"High sensitivity C\u2010reactive protein as a disease activity marker in rheumatoid arthritis","volume":"31","author":"Dessein PH","year":"2004","journal-title":"J Rheumatol"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.12972","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.12972","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.12972","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T23:55:07Z","timestamp":1694822107000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.12972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,24]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1111\/1756-185X.12972"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.12972","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,24]]},"assertion":[{"value":"2016-10-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}